StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
VKTXBullishCorporate Developmentsnews
High materiality7/10

Viking Therapeutics launches VK3019 Phase 1; expands obesity pipeline with VK2735 progress

Jun 24, 2026, 7:11 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Milestone-driven lift from IND clearance and Phase 1 start; potential uptick on VK3019 data; longer-term upside tied to VK2735 trial progress and oral-formulation potential.

AI summary

What happened, with direct paths to the underlying reporting

Viking Therapeutics announced the initiation of a Phase 1 single ascending dose study for VK3019, after FDA IND clearance, expanding its obesity-focused portfolio. The company also highlighted ongoing Phase 3 VANQUISH trials for VK2735 (GLP-1/GIP dual agonist) with an oral formulation in development and results expected for maintenance dosing in 3Q26. While early-stage, the VK3019 milestone coupled with VK2735's progression supports potential longer-term upside if early signals prove durable.

  • VK3019 Phase 1 SAD begins; IND cleared by FDA. BMI≥30 adults enrolled.
  • VK3019 DACRA targets amylin/calcitonin receptors for weight loss.
  • Preclinical data show up to 8% weight loss at 72 hours in animals.
  • VK2735 in Phase 3 VANQUISH; oral VK2735 planned later this year; 78-week trials.
  • Maintenance dosing results for VK2735 expected in 3Q26.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event